Abstract

Objective: There is limited literature focusing on the characteristics and behaviours of bladder tumours outside of the common three morphologies, that is, urothelial carcinoma, squamous cell carcinoma, and adenocarcinoma. The presented study provides a descriptive analysis of rare bladder tumours in KSA.

Methods: This retrospective cohort study included all patients with a primary rare bladder tumour between 1 January 2008 and 31 December 2017. The data were acquired from the Saudi Tumour Registry. Frequencies and percentages were then generated for the categorical variables, while means and standard deviations were calculated for quantitative variables.

Results: The study included 65 patients. The majority (n = 35, 53.8%) were aged 60 years and older. The patients were predominantly male (n = 53, 81.5%) and the majority lived in the Western region (n = 36, 55.4%). The most diagnosed tumour morphologies were small cell carcinoma. The presented study provides a descriptive characterisation of rare bladder tumours in KSA.

Conclusions: Our findings describe the clinical characteristics and outcomes of patients with rare bladder tumours in KSA. The study highlights the importance of further research to improve the understanding and management of these rare entities.
Introduction

Each year, more than 18 million new cases of cancer are diagnosed worldwide. Bladder cancer is one of the leading cancers in prevalence and has been increasing since the last decade.1 The Global Cancer Observatory ranks bladder cancers as the 11th leading cancer based on the number of new cases in KSA. Bladder cancers as an entity represent cancers.6 The remaining 20% are caused by non-urothelial carcinoma of the bladder include squamous cell carcinoma, small cell carcinoma, or undifferentiated carcinoma, malignant rhabdoid tumour, neuroendocrine carcinoma, paraganglioma, primitive neuroectodermal tumour, signet ring cell carcinoma, small cell carcinoma, or undifferentiated sarcoma, between 1 January 2008 and 31 December 2017. Patients diagnosed with metastatic bladder tumours were excluded from the study. The data were collected from the Saudi Cancer Registry (SCR), which collects tumour data from all private, military, and Health Ministry hospitals in KSA through five regional offices. The variables were grouped according to the year of diagnosis, gender, age, marital status, region, nationality, tumour’s site of origin, tumour histological subtype, tumour behaviour, tumour grade, tumour extent, tumour laterality, basis of the diagnosis, and survival. Data analysis was performed using the Statistical Package for the Social Sciences (SPSS) version 23.0 (IBM Corporation, NY, USA). Frequency and percentage were used to display the categorical variables, and mean and standard deviation for the continuous variables.

Results

A total of 65 patients were included in the study. Table 1 shows the socio-demographic profiles of the patients. The majority (n = 35, 53.8%) were aged 60 years and older. The mean age of the patients was 50.5 ± 27.7 years. Regarding gender, the population was predominantly male (n = 53, 81.5%). Considering nationality, 52 patients (80.7%) were Saudi, and 13 patients (20.2%) were non-Saudi. Regarding marital status, 15 patients (23.1%) were single, 64.6 patients (42%) were married, one patient (1.50%) was divorced, and 7 patients (10.8%) did not have a documented marital status. For the place of residency, 15 patients (23.1%) lived in the Central region, 11 patients (16.9%) in the Eastern region, 4 patients (6.20%) in the Northern region, 26 (40.0%) in the Western region, and 9 patients (13.8%) lived in the Southern region.

The tumour profiles of the patients are shown in Table 2. It shows the location of the tumour wherein one patient (1.50%) was in the trigone of the urinary bladder, one patient (1.50%) in the dome of the urinary bladder, 6 patients (9.20%) in the lateral wall of the urinary bladder, two patients (3.10%) in the anterior wall of the urinary bladder, two patient (3.10%) in the posterior wall of the urinary bladder, and 53 (81.5%) were multifocal tumours. Regarding the grades of tumours, other rare bladder tumours and tends to have a less favourable prognosis in children.10,11

In the global literature, there have been limited studies to improve the clinical outcomes of bladder tumours outside of the more common three morphologies, that is, urothelial carcinoma, squamous cell carcinoma, and adenocarcinoma. This may be attributed to the rarity of other malignancies. The presented study aims to provide a descriptive analysis of rare bladder tumours in the KSA.

Materials and Methods

This retrospective cohort study included patients diagnosed with primary bladder adenosquamous carcinoma, carcinosarcoma, clear cell adenocarcinoma, embryonal rhabdomyosarcoma, epithelioid leiomyosarcoma, epithelioid sarcoma, granular cell carcinoma, hemangioendothelioma, hemangiosarcoma, leiomyosarcoma, malignant rhabdoid tumour, neuroendocrine carcinoma, paraganglioma, primitive neuroectodermal tumour, signet ring cell carcinoma, small cell carcinoma, or undifferentiated sarcoma, between 1 January 2008 and 31 December 2017. Patients diagnosed with metastatic bladder tumours were excluded from the study. The data were collected from the Saudi Cancer Registry (SCR), which collects tumour data from all private, military, and Health Ministry hospitals in KSA through five regional offices. The variables were grouped according to the year of diagnosis, gender, age, marital status, region, nationality, tumour’s site of origin, tumour histological subtype, tumour behaviour, tumour grade, tumour extent, tumour laterality, basis of the diagnosis, and survival. Data analysis was performed using the Statistical Package for the Social Sciences (SPSS) version 23.0 (IBM Corporation, NY, USA). Frequency and percentage were used to display the categorical variables, and mean and standard deviation for the continuous variables.
4 patients (6.20%) had grade I tumours (well-differentiated), 4 patients (6.20%) had grade II tumours (moderately differentiated), 16 patients (24.6%) had grade III tumours (poorly differentiated), 7 patients (10.8%) had grade IV tumours (undifferentiated anaplastic), while 34 patients (52.3%) did not have a documented grade of the tumour.

Regarding the extension of the tumour, 60 patients (46.2%) had a localised tumour, 12 patients (18.5%) had a tumour with regional direct extension, one patient (1.50%) with regional lymph node extension, three patients (4.60%) with regional lymph node and direct extension, 14 patients (21.5%) had a tumour with distant metastasis, and 5 patients (7.70%) had no documentation of the extension.

Furthermore, the most common method used for the base of diagnosis was histology of the primary tumour in 64 patients (98.5%). For the year of incidence, 6 patients (9.20%) were diagnosed in 2008, one patient (1.50%) in 2009, 11 patients (16.90%) in 2010, one patient (1.50%) in 2011, 8 patients (12.30%) in 2012, 7 patients (10.80%) in 2013, 7 patients (10.80%) in 2014, 8 patients (12.30%) in 2015, 7 patients (10.80%) in 2016, and 9 patients (13.80%) were diagnosed in 2017.

Table 3 displays the various tumour morphologies. Among those younger than 18 years, 14 (21.5%) had embryonal rhabdomyosarcoma, while one patient (1.50%) had a malignant rhabdoid tumour. For those aged 18 years and older, two patients (3.10%) had adenosquamous carcinoma, 5 patients (7.70%) had carcinosarcoma, 4 patients (6.20%) had clear cell adenocarcinoma, one patient (1.50%) had epithelioid leiomyosarcoma, one patient (1.50%) had epithelioid sarcoma, one patient (1.50%) had granular cell carcinoma, three patients (4.60%) had malignant hemangiendothelioma, two patients (3.10%) had hemangiosarcoma, two patients (3.10%) had leiomyosarcoma, 6 patients (9.20%) had neuroendocrine carcinoma, two patients (3.10%) had malignant parangangioma, one patient (1.50%) had primitive neuroectodermal tumour, 8 patients (12.3%) had signet ring cell carcinoma, 11 patients (16.9%) had small cell carcinoma, and one patient (1.50%) had undifferentiated sarcoma.

Regarding patients’ last contact status, 49 patients (75.4%) were alive, while 16 patients (24.6%) died. All the deceased patients had cancer as the cause of death. Among the participating patients who died from cancer, the overall mean of the interval from diagnosis to death was 1.14 ± 0.75 years. The mean interval for each subtype was 1.08 ± 0.69 years for carcinosarcoma, 1.43 ± 0.62 years for signet ring cell carcinoma, and 0.84 ± 0.24 years for small cell carcinoma. The interval for other subtypes could not be calculated due to insufficient mortality numbers.

Discussion

This study suggests that both age and gender can predict the presence of rare bladder tumours, as 58.2% of the patients included in this study were over the age of 60 years, while male patients accounted for 81.5% of the cohort. Most...
patients identified were Saudi nationals (80.0%), single (42.0%), and resided in the western region (40.0%). Moreover, the tumour profile of each patient varied considerably, where 81.5% had multifocal tumours while 52.3% did not have a documented tumour grade. Regarding the extension of the tumour, a significant proportion of patients (46.2%) had a localised tumour. The most prevalent method of diagnosis was histology of the primary tumour, which was utilised in 98.5% of patients. Further, the tumour morphologies varied widely, with the most common presentations being embryonal rhabdomyosarcoma (21.5%), small cell carcinoma (16.9%), and signet ring cell carcinoma (12.3%). Almost a quarter of the patients (24.6%) included in this study died because of their cancer, while the mean interval from diagnosis to death in these patients was 1.14 years.

The male majority apparent in our study is reflected in the current literature, with a systematic review by Ismael et al. reporting on the incidence of small cell carcinoma. This rare bladder malignancy has a mean sex ratio of 5:1, ranging from 1:1 to 16:1 in the studies discussed in this review. However, a study by Fang et al. contradicts gender as a risk factor for rare bladder tumours, with the patient demographics in this study indicating a 3:1 female-to-male incidence of pancreatic tumours. Despite this contradiction, their study supports our findings that the prevalence of rare tumours of the bladder is enhanced in those over 60 years of age, with Fang et al. reporting a mean age of 64.5 years in a cohort of 45 patients. However, it has been suggested that age is significantly related to the histological subtype of rhabdomyosarcoma. Gaal et al. assessed the impact of age on the outcome of both embryonal and alveolar rhabdomyosarcoma patients in a multicentre study, and the data indicated that patients over 16-years had a higher rate of alveolar subtypes and tumours arising at unfavourable sites. Moreover, the incidence of lymph node involvement, rate of distant metastasis, and incidence of relapse were all significantly higher in those over the age of 16 years compared to the patients under 16 years. Although not directly corroborating our findings—suggesting that the elderly population is at a greater risk of developing rare bladder tumours—their study provides evidence that children and adolescents have a greater possibility of complete remission.

A study by Shaaban et al. had similar purpose as this study and assessed the incidence of squamous cell carcinoma of the urinary bladder in patients treated at the Riyadh Armed Forces Hospital between 1979 and 1995. Several similar results about patient demographics were noted. First, among the patients under study, the proportion of Saudi nationals diagnosed with transitional cell carcinoma was 71%, while 68% had squamous cell carcinoma. Moreover, the male-to-female ratio was 8:1 for transitional cell carcinoma patients and 4.2:1 for those with squamous cell carcinoma. These findings align with those of our study.

Detecting bladder cancer encompasses several diagnostic measures, including cytology and morphology-based assays, in addition to biochemical and molecular markers. Cytoscopy is widely accepted as the gold standard for the detection of bladder tumours; however, several studies have highlighted the importance of histology in diagnosis, as numerous tumour types reflect a characteristic histological appearance. Hence, histology, as the most prevalently employed method in the diagnosis of bladder cancer utilised in our cohort, was validated by the evidence presented in the literature.

Concerning tumour characteristics, the current literature corroborates the high incidence of patients with multifocal tumours, and several studies have also suggested that this multifocality is a determinant of disease prognosis. Wu et al. evaluated this hypothesis in a meta-analysis of patients with upper tract urothelial carcinoma. The findings provided evidence that both ureteral and multifocal tumours can be defined as independent prognosticators of disease progression and cancer-specific survival of patients with upper tract urothelial carcinoma. These reduced survival of patients with multifocal tumours, provides a rationale for the high mortality rate (24.6%) among patients included in this study. The current literature also suggests other poor prognostic factors for this disease, including lymph vascular invasion, recurrence, large tumour size, presence of urothelial carcinoma in situ, and multicentricity.

There were some limitations to this study. First, because it was retrospective, the research team members had to rely on other individuals for accurate and safe record keeping. Second, the issue of underreporting might be present, which may reduce the validity of our findings and the literature and is generally defined as a source of systematic error in cancer research. Third, the diagnosis to death interval could not be calculated for all morphologies due to an insufficient number of mortalities among them.

**Conclusion**

Formulating a global registry for such patients is advised to facilitate extensive investigations to improve our knowledge about the diagnosis and treatment of such rare entities. Additionally, future studies should focus on biomarker
findings with translational and clinical implications. Similar to the available literature, the tumours discussed in the study have been associated with a poor outcome and a short diagnosis to death interval, possibly due to the lack of investigations providing a level one evidence for management methods. There remains a gap in the literature regarding uncommon urologic tumours. Sheding light on them will aid in a better understanding of the patterns of tumour behaviour in the region. This will allow for enhanced risk-and response-based screening strategies and more favourable outcomes.

**Source of funding**

This research did not receive any funding from institutions in the public, commercial, or not-for-profit sectors.

**Conflict of interest**

The authors have no conflict of interest to declare.

**Ethical approval**

The study was approved by the Institutional Review Board of King Abdullah International Medical Research Center, Ministry of National Guard Health Affairs, Riyadh, KSA (approval number NRC21R/085/03) on March 23rd, 2021. Patient confidentiality was ensured, and the patients’ data were collected and used by the research team only. Serial numbers were used instead of medical record numbers to ensure anonymity. Due to the retrospective nature of the study and the use of anonymised patient data, the requirement for informed consent was waived.

**Authors contributions**

MAQ, MAG, ZFM, SMW, and AA formulated the idea, designed methods, validated the study, and provided research materials. MAQ, ZFM, and AA curated and analysed the data, interpreted, and presented the results. MAG and SMW wrote the original draft of the manuscript. AA critically revised the original draft for important intellectual content, supervised, and administered the project. All authors have critically reviewed and approved the final draft and are responsible for the content and similarity index of the manuscript.

**Acknowledgment**

The authors would like to thank the Saudi Cancer Registry for providing access to data for research purposes.

**References**

1. International Agency for Research on Cancer. *Global bladder cancer statistics; 2020* [https://gco.iarc.fr/today/data-factsheets/cancers/30-Bladder-fact-sheet.pdf]. [Accessed 23 July 2021].
2. Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. *Urol 2005;* 66: 4–34. [https://doi.org/10.1016/j.urology.2005.07.062].
3. Lenis AT, Lee PM, Chami K. Bladder cancer: a review. *Jama 2020;* 324: 1980–1991. [https://doi.org/10.1001/jama.2020.17598].
4. Cumberbatch MG, Jubber I, Black PC, Esperto F, Figueirosa JD, Kamat AM, et al. Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018. *Eur Urol 2018;* 74: 784–795. [https://doi.org/10.1016/j.eururo.2018.09.001].
5. Mun DH, Kimura S, Sharatif SF, Abutaraf M. The impact of gender on oncologic outcomes of bladder cancer. *Curr Opin Urol 2019;* 29: 279–285. [https://doi.org/10.1097/MOU.0000000000000606].
6. Willis D, Kamat AM. Nonurothelial bladder cancer and rare variant histologies. *Hematol Oncol Clin 2015;* 29: 237–252. [https://doi.org/10.1016/j.hoc.2014.10.011].
7. Jozwicki W, Domaniewski J, Skok Z, Wolski Z, Domanowska E, Jozwicka G. Usefulness of histologic homogeneity estimation of muscle-invasive urinary bladder cancer in an individual prognostic; a mapping study. *Urol 2005;* 66: 1122–1126. [https://doi.org/10.1016/j.urology.2005.06.134].
8. Park S, Reuter VE, Hansel DE. Non-urothelial carcinomas of the bladder. *Histopathol 2019;* 74: 97–111. [https://doi.org/10.1111/his.13719].
9. Ismaili N. A rare bladder cancer-small cell carcinoma: review and update. *Orphanet J Rare Dis 2011;* 6. [https://doi.org/10.1186/1750-1172-6-75].
10. Aggarwal A, Singh V, Pandey S, Sinha RJ. Embryonal rhabdomyosarcoma of urinary bladder in an adult patient: an unusual manifestation. *Case Rep 2018;* 1–3. [https://doi.org/10.1136/bcr-2018-224255].
11. Castagnetti M, Herbst KW, Esposito C. Current treatment of pediatric bladder and prostate rhabdomyosarcoma (bladder preserving vs. radical cytostectomy). *Curr Opin Urol 2019;* 29: 487–492. [https://doi.org/10.1097/MOU.0000000000000651].
12. Fang D, Liu P, Li X, Xiong G, Zhang L, Singla N, et al. Characteristics and treatment outcomes of pan-urothelial cell carcinoma: a descriptive analysis of 45 patients. *Sci Rep 2015;* 5: 1–9. [https://doi.org/10.1186/srep18014].
13. Van Gaal JC, Van der Graaf WT, Rikhof B, Van Hoesel QG, Teerenstra S, Suurmeijer AJ, et al. The impact of age on outcome of embryonal and alveolar rhabdomyosarcoma patients. A multicenter study. *Anticancer Res 2012;* 32: 4485–4497.
14. Shaaban AA, Orkubi SA, Said MT, Yousef B, Abomelha MS. Squamous cell carcinoma of the urinary bladder. *Ann Saudi Med 1997;* 17: 115–119. [https://doi.org/10.5144/0256-4947.1997.115].
15. Essa S, Kassim S, El-Ahmady O. Detection of bladder tumours: role of cytology, morphology-based assays, biochemical and molecular markers. *Curr Opin Obstet Gynecol 2003;* 15: 395–403. [https://doi.org/10.1097/00001703-200310000-00008].
16. Black AJ, Black PC. Variant histology in bladder cancer: diagnostic and clinical implications. *Transl Cancer Res 2020;* 9(10): 6565–6575. [https://doi.org/10.21037/tcr-20-2169].
17. Wu Y, Dong Q, Liu L, Han P, Wei Q. The impact of tumor location and multifocality on prognosis for patients with upper tract urothelial carcinoma: a meta-analysis. *Sci Rep 2014;* 4(1): 1–8. [https://doi.org/10.1186/srep06361].
18. Babjuk M, Böhm A, Burger M, Capoun O, Cohen D, Comperat EM, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. *Eur Urol 2017;* 71(3): 447–461. [https://doi.org/10.1016/j.eururo.2016.05.041].

**How to cite this article:** Alqahtani MA, Alghafees MA, Musalli ZF, Alwatab SM, Alaker A. Rare tumours of the bladder: A Saudi registry based descriptive study. *J Taibah Univ Med Sc* 2022;17(4):573–577.